SCHEMBL7224703

SCHEMBL7224703

O=C(Nc1cccc2cc(S(=O)(=O)O)ccc12)c1cc(NS(=O)(=O)c2ccc(Cl)cc2)cc(C(=O)Nc2cccc3cc(S(=O)(=O)O)ccc23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.55
WDR5 P61964 1/20 0.52
FGF1 P05230 1/20 0.49
TIMP3 P35625 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDR P35968 4/20 0.46
EGFR P00533 3/20 0.46
FGFR1 P11362 3/20 0.46
CYP19A1 P11511 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
GPR27 Q9NS67 1/20 0.43
GBA1 P04062 1/20 0.43
MAPT P10636 2/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
TP53 P04637 1/20 0.43
NAMPT P43490 1/20 0.43
CYP2C9 P11712 1/20 0.42
ATIC P31939 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7223951 0.92 CASP6 (0.57) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7230646 0.90 CASP6 (0.55) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7232469 0.90 CASP6 (0.58) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7233109 0.89 FGF1 (0.59) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7223386 0.88 CASP6 (0.56) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7226724 0.88 FGF1 (0.62) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7230479 0.87 CASP6 (0.55) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL6240628 0.85 CASP6 (0.72) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7233931 0.85 CASP6 (0.57) CASP6FGF1TIMP3MEN1KMT2A
SCHEMBL7223974 0.84 CASP6 (0.54) CASP6FGF1TIMP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653321-B1 Stimulating kinase activity of insulin receptor; type II diabetes; hyperglycemia TELIK, INC. 2003-11-25 US disclosed